CLU and Alzheimer disease: Since clusterin has recently already been proposed as a therapeutic target for AD [84], its regulatory potential to reverse the expression of multiple downstream sex-dependent DEGs indicates that it could also serve as a candidate target to address sex-specific pathological changes in AD.